| Report | Options implied | Actual move | Market was |
|---|---|---|---|
| 07/23/2026 | ±2.6% | -0.8% | over-priced |
| 04/23/2026 | ±2.4% | +12.9% | under-priced |
| 02/17/2026 | ±5.1% | -2.9% | over-priced |
| 10/23/2025 | ±2.5% | +10.9% | under-priced |
| 07/24/2025 | ±4.0% | +22.8% | under-priced |
| 04/24/2025 | ±4.5% | -3.5% | over-priced |
| 02/18/2025 | ±15.8% | -1.7% | over-priced |
| 10/24/2024 | ±2.1% | +15.4% | under-priced |
| Quarter | EPS (dil.) | Revenue | Net income |
|---|---|---|---|
| Q2 FY2026 | $2.15 | $872M | $154M |
| Q1 FY2026 | $1.92 | $845M | $139M |
| Q4 FY2025 | — | $805M | $132M |
| Q3 FY2025 | $1.92 | $805M | $140M |
West Pharmaceutical Services, Inc. (WST) reports in 83 days, with the next report estimated for 01/19/2027. Across the last 8 reports, options priced an average ±4.9% earnings move while the stock actually moved 8.9% on average — the market has been roughly fair on WST's earnings risk. Fundamentals into the print: EPS up 18.1% year-over-year, revenue up 13.8%. QuantLogix's live 5-factor engine currently reads WST as a buy at 86/100.
Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →